201 related articles for article (PubMed ID: 34638761)
21. Mechanistic Understanding Enables the Rational Design of Salicylanilide Combination Therapies for Gram-Negative Infections.
Copp JN; Pletzer D; Brown AS; Van der Heijden J; Miton CM; Edgar RJ; Rich MH; Little RF; Williams EM; Hancock REW; Tokuriki N; Ackerley DF
mBio; 2020 Sep; 11(5):. PubMed ID: 32934086
[TBL] [Abstract][Full Text] [Related]
22. Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.
Jin B; Wang C; Shen Y; Pan J
Cell Death Dis; 2018 Jan; 9(2):68. PubMed ID: 29358661
[TBL] [Abstract][Full Text] [Related]
23. Repurposing of niclosamide as a STAT3 inhibitor to enhance the anticancer effect of chemotherapeutic drugs in treating colorectal cancer.
Wu MM; Zhang Z; Tong CWS; Yan VW; Cho WCS; To KKW
Life Sci; 2020 Dec; 262():118522. PubMed ID: 33011217
[TBL] [Abstract][Full Text] [Related]
24. Metabolomic analyses uncover an inhibitory effect of niclosamide on mitochondrial membrane potential in cholangiocarcinoma cells.
Kulthawatsiri T; Kittirat Y; Phetcharaburanin J; Tomacha J; Promraksa B; Wangwiwatsin A; Klanrit P; Titapun A; Loilome W; Namwat N
PeerJ; 2023; 11():e16512. PubMed ID: 38025687
[TBL] [Abstract][Full Text] [Related]
25. Niclosamide is a Negative Allosteric Modulator of Group I Metabotropic Glutamate Receptors: Implications for Neuropathic Pain.
Ai N; Wood RD; Yang E; Welsh WJ
Pharm Res; 2016 Dec; 33(12):3044-3056. PubMed ID: 27631130
[TBL] [Abstract][Full Text] [Related]
26. Discovery of degradable niclosamide derivatives able to specially inhibit small cell lung cancer (SCLC).
He X; Li M; Ye W; Zhou W
Bioorg Chem; 2021 Feb; 107():104574. PubMed ID: 33383327
[TBL] [Abstract][Full Text] [Related]
27. [Molecular mechanisms of niclosamide antitumor activity].
Moskaleva EY; Perevozchikova VG; Zhirnik AS; Severin SE
Biomed Khim; 2015; 61(6):680-93. PubMed ID: 26716739
[TBL] [Abstract][Full Text] [Related]
28. [Antineoplastic mechanisms of niclosamide-loaded nanoparticles in human colorectal cancer cells].
Zhirnik AS; Semochkina YP; Moskaleva EY; Krylov NI; Tubasheva IA; Kuznetsov SL; Vorontsov EA
Biomed Khim; 2017 Mar; 63(2):132-138. PubMed ID: 28414284
[TBL] [Abstract][Full Text] [Related]
29. The magic bullet: Niclosamide.
Jiang H; Li AM; Ye J
Front Oncol; 2022; 12():1004978. PubMed ID: 36479072
[TBL] [Abstract][Full Text] [Related]
30. Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells.
Pan JX; Ding K; Wang CY
Chin J Cancer; 2012 Apr; 31(4):178-84. PubMed ID: 22237038
[TBL] [Abstract][Full Text] [Related]
31. Niclosamide as a Promising Therapeutic Player in Human Cancer and Other Diseases.
Wang Z; Ren J; Du J; Wang H; Liu J; Wang G
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555754
[TBL] [Abstract][Full Text] [Related]
32. Autophagy-Inducing Inhalable Co-crystal Formulation of Niclosamide-Nicotinamide for Lung Cancer Therapy.
Ray E; Vaghasiya K; Sharma A; Shukla R; Khan R; Kumar A; Verma RK
AAPS PharmSciTech; 2020 Sep; 21(7):260. PubMed ID: 32944787
[TBL] [Abstract][Full Text] [Related]
33. Anthelmintic niclosamide attenuates pressure-overload induced heart failure in mice.
Fu Y; Hu N; Cao M; Li WF; Yang XR; Gao JL; Zhao J; Jiang M; Ma MH; Sun ZJ; Dong DL
Eur J Pharmacol; 2021 Dec; 912():174614. PubMed ID: 34736968
[TBL] [Abstract][Full Text] [Related]
34. Niclosamide: Beyond an antihelminthic drug.
Chen W; Mook RA; Premont RT; Wang J
Cell Signal; 2018 Jan; 41():89-96. PubMed ID: 28389414
[TBL] [Abstract][Full Text] [Related]
35. Niclosamide-conjugated polypeptide nanoparticles inhibit Wnt signaling and colon cancer growth.
Bhattacharyya J; Ren XR; Mook RA; Wang J; Spasojevic I; Premont RT; Li X; Chilkoti A; Chen W
Nanoscale; 2017 Aug; 9(34):12709-12717. PubMed ID: 28828438
[TBL] [Abstract][Full Text] [Related]
36. In Vitro Evaluation and Mitigation of Niclosamide's Liabilities as a COVID-19 Treatment.
Wotring JW; McCarty SM; Shafiq K; Zhang CJ; Nguyen T; Meyer SR; Fursmidt R; Mirabelli C; Clasby MC; Wobus CE; O'Meara MJ; Sexton JZ
bioRxiv; 2022 Jul; ():. PubMed ID: 35860224
[TBL] [Abstract][Full Text] [Related]
37. Repurposing of the anti-helminthic drug niclosamide to treat melanoma and pulmonary metastasis via the STAT3 signaling pathway.
Zhu Y; Zuo W; Chen L; Bian S; Jing J; Gan C; Wu X; Liu H; Su X; Hu W; Guo Y; Wang Y; Ye T
Biochem Pharmacol; 2019 Nov; 169():113610. PubMed ID: 31465777
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of LEF1-Mediated DCLK1 by Niclosamide Attenuates Colorectal Cancer Stemness.
Park SY; Kim JY; Choi JH; Kim JH; Lee CJ; Singh P; Sarkar S; Baek JH; Nam JS
Clin Cancer Res; 2019 Feb; 25(4):1415-1429. PubMed ID: 30446587
[TBL] [Abstract][Full Text] [Related]
39. Niclosamide-loaded polymeric micelles ameliorate hepatocellular carcinoma in vivo through targeting Wnt and Notch pathways.
Zeyada MS; Abdel-Rahman N; El-Karef A; Yahia S; El-Sherbiny IM; Eissa LA
Life Sci; 2020 Nov; 261():118458. PubMed ID: 32961231
[TBL] [Abstract][Full Text] [Related]
40. The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma
Zhou J; Jin B; Jin Y; Liu Y; Pan J
Theranostics; 2017; 7(6):1447-1462. PubMed ID: 28529629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
